CAJ | 학술논문

目的　探讨生长抑素（sst）在乳腺癌中诊断和治疗的价值。方法　应用免疫组织化学方法对30例原发性乳腺癌患者行sst和ER PR的表达。结果　有同侧腋窝淋巴结转移患者11例，其中8例sst(+)；无同侧腋窝淋巴结转移者19例，其中7例sst(+)，两组差异有显著性 ( χ2=3.6 , P＜0.05) 。良性乳腺瘤10例；其中4 例sst(+)与20例乳腺癌sst(+)相比，两组差异有非常显著性 (χ2=9.22,P＜0.01)。结论　sst对原发性乳腺癌诊断及治疗有一定的潜力。
목적　탐토생장억소（sst）재유선암중진단화치료적개치。방법　응용면역조직화학방법대30례원발성유선암환자행sst화ER PR적표체。결과　유동측액와림파결전이환자11례，기중8례sst(+)；무동측액와림파결전이자19례，기중7례sst(+)，량조차이유현저성 ( χ2=3.6 , P＜0.05) 。량성유선류10례；기중4 례sst(+)여20례유선암sst(+)상비，량조차이유비상현저성 (χ2=9.22,P＜0.01)。결론　sst대원발성유선암진단급치료유일정적잠력。
Objective　To evaluate the expression of Somatostatin(SST) in diagnoses and Treatment of breast cancer.Method　 30 cases of primary breast cancer were studied in expression of Somatostatin(SST) and ER, PR with Immunohistochemicaty assay.Result　20 cases of patients in total 30 cases demonstrate SST positive. 8 SST positive in 19 patients with lateral lymph node negative. (χ2=3.6 P＜0.05). Compared with 10 cases of benign lesion of breast in which 4 cases show SST positive, 20 cases show SST positive in 30 cases of malignant lesions(χ2=9.22 P＜0.01).Conclusion　Somatostatin(SST) plays a role diagnosis and treatment of primary breast cancer, but had better prognosis in patients with SST breast cancer.